Company intelligence / Profile preview
ReacX Pharmaceuticals
South San Francisco, California, United Statesreacxpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ReacX Pharmaceuticals is developing proprietary therapeutics using its ProNeura® platform, which enables long-term, continuous subdermal drug delivery. Its lead product, Probuphine® (buprenorphine implant), is FDA-approved for maintenance treatment of opioid dependence and delivers medication continuously for six months. The company is also advancing a nalmefene implant to prevent relapse in OUD patients post-detoxification. No active clinical trials are currently listed on ClinicalTrials.gov as of June 2025.
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculeImplantable drug delivery system
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not disclosed
Beyond the preview
Go deeper on ReacX Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReacX Pharmaceuticals.